Obstructive sleep apnea/hypopnea syndrome (OSAHS) is a very common disease, affecting a large percentage of the population. It is estimated that between 9% and 26% of adults, and up to 3% of children, suffer from it.
Obstructive sleep apnea occurs when there is an obstruction in the airway during sleep. After which breathing returns with a snore or snort. Sufferers stop breathing for periods longer than 10 seconds, even up to 2 minutes, throughout the night.
These respiratory arrests cause alterations in heart rate, tiredness, drowsiness and irritability, which can affect the course of normal life and even lead to traffic and work-related accidents.
The conventional treatment recommended for OSAHS is CPAP: a mask connected to an air pump that administers constant pressure to the patient during the night, to prevent the throat from "closing". More than a third of patients do not tolerate the CPAP mask and abandon the treatment.
There are also other less popular treatments, such as mandibular augmentation devices (MAD) and surgical treatments.
For those affected by apnea and hypopnea that do not admit conventional treatments, the new Kalinix device offers an effective, non-invasive and even permanent alternative to existing OSAHS treatments currently on the market.
Kalinix is an electromedical apnea and hypopnea detection and treatment device that detects and treats respiratory arrest in real time.
Provides accurate, clinically proven results.
Provides accurate results and stores them, with clarity in the display of critical performance points.
It does not require surgery and its medical use is simple.
Multi-sensor data collection offers a large margin of action in the detection of events.
The results can be displayed on the screen
It is light, quiet, discreet, resistant and portable. It makes it easy for the patient to accept and use.
Kalinix's technology for the detection and treatment of apnea is based on a smart, wearable, mobile phone-sized, multi-sensor and self-adaptive device.
Thanks to its Artificial Intelligence, it performs predictive detection and real-time treatment of respiratory arrest by means of specific stimulation waves.
Kalinix is a non-invasive solution which minimizes side effects and increases patient acceptance.
Kalinix offers a potential improvement solution for OSAHS thanks to its therapeutic treatment.
Previous studies carried out at the Pneumology Department of the Hospital Clínico San Carlos directed by Prof. Dr. José Luís Álvarez Sala Walther, the Hospital Teknon in Barcelona and the collaboration of Dr. Ernesto Delgado Cidranes of the Hospital Vithas La Milagrosa, led to the hypothesis that, with the toning of the muscles associated with the physiopathology of OSAHS, there could be an improvement in the main parameters of sleep.
Kalinix allows to perform a simplified sleep study.
Kalinix is currently in the validation phase of clinical trials at the Hospital Clínico San Carlos and in the process of obtaining the CE marking.
To keep up to date with all the news and advances in the launch of Kalinix you can follow us on our social networks: